COEP — Coeptis Therapeutics Holdings Balance Sheet
0.000.00%
- $74.14m
- $73.43m
Annual balance sheet for Coeptis Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K/A | 10-K | 10-K | 10-Q | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.907 | 0.404 | 3.79 | 1.47 | 0.533 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 0.008 | 0.039 | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.959 | 0.413 | 3.94 | 1.75 | 1.05 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | — | 0.071 | 0.109 | 0.07 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 76.7 | 76.2 | 7.92 | 4.57 | 8.91 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.005 | 0.14 | 2.17 | 2.99 | 4.51 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 23 | 7.19 | 3.46 | 3.76 | 5.72 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 53.8 | 69 | 4.45 | 0.814 | 3.19 |
| Total Liabilities & Shareholders' Equity | 76.7 | 76.2 | 7.92 | 4.57 | 8.91 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |